NEW YORK (GenomeWeb News) – Asuragen and Life Technologies have entered into an exclusive agreement to develop and commercialize a molecular diagnostic test to aid physicians in monitoring and treating patients with chronic myeloid leukemia.

Asuragen's BCR/ABL1 assay will simultaneously detect and quantify BCR/ABL1 fusion transcripts (b2a2, b3a2, and e1a2) in a single reaction, Austin, Texas-based Asuragen said. The BCR/ABL1 fusion transcripts are present in roughly 95 percent of CML and 25 percent to 30 percent of patients with acute lymphoblastic leukemia, the firm added.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: Akt3 amplification in glioma progression, Tibetan Plateau frog genome, and more.

The US Supreme Court has declined to review a decision involving the use of "inadvertently shed" DNA in a police investigation and subsequent conviction.

A panel at the New York Times discusses anonymity and privacy of users of 23andMe's services when access to its database is offered for research.

National Institutes of Health Director Francis Collins appears before a House subcommittee to discuss his agency's budget request.